Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6583954 | 0.90 | PTPN1 (0.33) | PTPN1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL6579684 | 0.88 | PTPN1 (0.38) | PTPN1KDM4E | |
| SCHEMBL6582762 | 0.85 | LMNA (0.38) | PTPN1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL6579735 | 0.82 | PTPN1 (0.31) | PTPN1 | |
| SCHEMBL6582439 | 0.82 | PTPN1 (0.39) | PTPN1TP53MAPTRXFP1 | |
| SCHEMBL6585784 | 0.81 | PTPN1 (0.32) | PTPN1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL4213178 | 0.81 | PPARG (0.33) | — | |
| SCHEMBL4211420 | 0.78 | PDE4D (0.36) | PTPN1KDM4EALDH1A1MAPT | |
| SCHEMBL7065995 | 0.78 | PTPN1 (0.32) | PTPN1 | |
| SCHEMBL6580469 | 0.77 | PTPN1 (0.37) | PTPN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401822-A1 | NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2004-03-31 | — | — | EP | claimed |
| US-6599925-B2 | Cardiovascular disorders; anticancer agents | WYETH | 2003-07-29 | — | — | US | claimed |
| US-20030018067-A1 | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH | 2003-01-23 | — | — | US | claimed |
| WO-2003000671-A1 | NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | claimed |
| US-6599925-B2 | Cardiovascular disorders; anticancer agents | WYETH | 2003-07-29 | — | — | US | disclosed |
| US-20030018067-A1 | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018067-A1 | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | F2R, SERPINE1, SERPINC1 | PTPN1 1287/4885KDM4E 4021/4885ALDH1A1 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.